CL2022000089A1 - Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida. - Google Patents

Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.

Info

Publication number
CL2022000089A1
CL2022000089A1 CL2022000089A CL2022000089A CL2022000089A1 CL 2022000089 A1 CL2022000089 A1 CL 2022000089A1 CL 2022000089 A CL2022000089 A CL 2022000089A CL 2022000089 A CL2022000089 A CL 2022000089A CL 2022000089 A1 CL2022000089 A1 CL 2022000089A1
Authority
CL
Chile
Prior art keywords
inden
polymorphs
carboxamide
dihydro
isopropyl
Prior art date
Application number
CL2022000089A
Other languages
English (en)
Spanish (es)
Inventor
Norma TOM
Denise Andersen
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CL2022000089A1 publication Critical patent/CL2022000089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2022000089A 2019-07-17 2022-01-12 Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida. CL2022000089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17

Publications (1)

Publication Number Publication Date
CL2022000089A1 true CL2022000089A1 (es) 2022-10-07

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000089A CL2022000089A1 (es) 2019-07-17 2022-01-12 Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.

Country Status (16)

Country Link
US (1) US20220274969A1 (https=)
EP (1) EP3999181B1 (https=)
JP (1) JP2022542803A (https=)
KR (1) KR20220082803A (https=)
CN (1) CN114667283B (https=)
AU (1) AU2020315433A1 (https=)
BR (1) BR112022000523A2 (https=)
CA (1) CA3144974A1 (https=)
CL (1) CL2022000089A1 (https=)
ES (1) ES2982707T3 (https=)
IL (1) IL289881A (https=)
MX (1) MX2022000498A (https=)
NZ (1) NZ784931A (https=)
PH (1) PH12022550084A1 (https=)
TW (1) TW202116764A (https=)
WO (1) WO2021011809A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
US20220274969A1 (en) 2022-09-01
IL289881A (en) 2022-03-01
EP3999181B1 (en) 2024-05-29
CN114667283B (zh) 2023-12-26
CN114667283A (zh) 2022-06-24
KR20220082803A (ko) 2022-06-17
AU2020315433A1 (en) 2022-03-03
JP2022542803A (ja) 2022-10-07
NZ784931A (en) 2025-03-28
PH12022550084A1 (en) 2023-04-12
ES2982707T3 (es) 2024-10-17
CA3144974A1 (en) 2021-01-21
EP3999181A1 (en) 2022-05-25
TW202116764A (zh) 2021-05-01
MX2022000498A (es) 2022-02-03
EP3999181C0 (en) 2024-05-29
WO2021011809A1 (en) 2021-01-21
BR112022000523A2 (pt) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2022000054A1 (es) Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-car- boxamida.
CL2022000089A1 (es) Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
JOP20200194A1 (ar) صور بلورية جديدة
CO2018004124A2 (es) Compuestos heterocíclicos
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
DK3827004T3 (da) 4-(1,3,4-oxadiazol-2-yl)pyridin-2(1h)-on-derivater som histondeacetylase-6 (hdac6) hæmmere til behandling af f.eks, infektioner
EP3789382A4 (en) PROCESS FOR THE PRODUCTION OF 4,5-DIHYDROISOXAZOLE 5,5-DISUBSTITUTED
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
IL260403B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
UY38017A (es) Polimorfos de 4-[5-(3,5-dicloro-4-fluorofenil)-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-(2-etil-3-oxo-4-isoxazolidinil)-2-metilbenzamida
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
PH12020500674A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
MX2022007660A (es) Tiofenocarboxamidas sustituidas y sus derivados.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
MX381722B (es) Compuestos.
CO2021003295A2 (es) (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso
HK40074727A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
UY36982A (es) Modificación cristalina termodinámicamente estable de 2–metil–n–(5–metil–1,3,4–oxadiazol–2–il)–3–(metilsulfonil)–4–(trifluorometil)benzamida
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.